|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Capecitabine and irinotecan with and without bevacizumab for advanced colorectal cancer patients显示文摘AIM:To investigate the efficacy and safety of capecitabine plus irinotecan±bevacizumab in advanced or metastatic colorectal cancer patients. METHODS:Forty six patients with previously untreated,locally-advanced or metastatic colorectal cancer(mCRC) were recruited between 2001-2006 in a prospective open-label phaseⅡtrial,in German community-based outpatient clinics.Patients received a standard capecitabine plus irinotecan(CAPIRI) or CAPIRI plus bevacizumab(CAPIRI-BEV) regimen every 3 wk. Dose reductions were mandatory from the first cycle in cases of>grade 2 toxicity.The treatment choice of bevacizumab was at the discretion of the physician.Theprimary endpoints were response and toxicity and secondary endpoints included progression-free survival and overall survival. RESULTS:In the CAPIRI group vs the CAPRI-Bev group there were more female than male patients(47% vs 24%) ,and more patients had colon as the primary tumor site(58.8%vs 48.2%) with fewer patients having sigmoid colon as primary tumor site(5.9%vs 20.7%) .Grade 3/4 toxicity was higher with CAPIRI than CAPIRI-Bev:82%vs 58.6%.Partial response rates were 29.4%and 34.5%,and tumor control rates were 70.6%and 75.9%,respectively.No complete responses were observed.The median progression-free survival was 11.4 mo and 12.8 mo for CAPIRI and CAPIRI-Bev,respectively.The median overall survival for CAPIRI was 15 mo(458 d) and for CAPIRI-Bev 24 mo(733 d) .These differences were not statistically different.In the CAPIRI-Bev,group,two patients underwent a full secondary tumor resection after treatment,whereas in the CAPIRI group no cases underwent this procedure. CONCLUSION:Both regimens were well tolerated and offered effective tumor growth control in this outpatient setting.Severe gastrointestinal toxicities and thromboembolic events were rare and if observed were never fatal. | Markus Moehler Martin F Sprinzl Murad Abdelfattah Carl C Schimanski Bernd Adami Werner Godderz Klaus Majer Dimitri Flieger Andreas Teufel Juergen Siebler Thomas Hoehler Peter R Galle Stephan Kanzler | 2009 | World Journal of Gastroenterology2009，15，4： | 10 |
| 2 | Optimized extraction of micro- cystins from field samples : a comparison of different solvents and proce- dures 显示文摘 | Fastner J Flieger I Nuemann U | 1998 | Water Res1998，32，10： | 1 |
| 3 | A bispecific single-chain antibody directed against EpCAM/CD3 in combination with the cytokines interferon alpha and interleukin-2 efficiently retargets T and CD3+CD56+ natural-killer-like T lymphocytes to EpCAMexpressing tumor cells显示文摘 | Flieger D Kufer P Beier I | 2000 | Cancer Immunol Immunother2000，49，8： | 1 |
| 4 | Ergot alkaloids: sources,structures and analytical methods显示文摘 | FLIEGER M WURST M SHELBY R | 1997 | Folia Microbiol1997，42，1： | 1 |
| 5 | 显示文摘 | Fanali S Flieger M Sreinerova N | 1992 | Electrophoresis1992，131，1： | 1 |
| 6 | Disease resistance gene analogs as candidates for QTLs involved in pepper-pathogen interactions 显示文摘 | Flieger S P Lefebvre V Caranta C | 1999 | G enome1999，42，： | 1 |
| 7 | Regulated secretion of macrophage migration inhibitory factor is mediated by a non-classical pathway involving an ABC transporter显示文摘 | Flieger O Engling A Bucala R | 2003 | FEBS Lett2003，551，1： | 1 |
| 8 | Therapeutic vaccination against metastatic renal cell carcinoma by autologous dendritic cells: Preclinical results and outcome of a first clinical phase Ⅰ/Ⅱ trial 显示文摘 | Marten A Flieger D Renoth S | 2002 | Cancer Immunol Immunother2002，51，12： | 1 |
| 9 | Mechanical stimula- tion in the form of vibration prevents postmenopausal bone loss in ovariectomized rats 显示文摘 | Flieger J Karachalios T Khaldi L | 1998 | Calcif Tissue Int1998，63，6： | 1 |
| 10 | Therapeutic vaccination against metastatic renal cell carcinoma by autologous dendritic cells:Preclinical results and outcome of a first clinical phase Ⅰ/Ⅱ trial显示文摘 | Marten A Flieger D Renoth S | 2002 | Cancer Immunol Immunother2002，51，1112： | 1 |
| 11 | Biodegradable Plastics from Renewable Sources 显示文摘 | Flieger M Kantorova M Prell A | 2003 | Folia Microbiol2003，48，1： | 1 |
| 12 | Self-expanding metal stents for malignant esophagogastric obstruction:experience with a new design coverednitinol stent显示文摘 | Keller R Flieger D Fischbach W | | 0，，03： | 1 |
| 13 | Therapeutic vaccination against metastatic renal cell carcinoma by autologous dendritic cells: preclinical results and outcome of a first clinical phaseⅠ/Ⅱ trial显示文摘 | Marten A Flieger D Renoth S | 2002 | Cancer Immunol Immunother2002，51，1112： | 1 |
| 14 | Intracellular action of the cytokine MIF to modulate AP-1 sctivity and the cell cycle through Jab1显示文摘 | Kleeman R Hausser A Geiger G Mischke R Burger-Kentischer A Flieger O | 2000 | Nature2000，408，： | 1 |
| 15 | Dexamethasone,high-dose cytarabine and cisplatin in combination with rituximab as salvage treatment for patients with relapsed or refractory aggressive non-Hodgkins lymphoma显示文摘 | Mey UJ Orlopp KS Flieger D | 2006 | Cancer Invest2006，24，6： | 1 |
| 16 | Mechanism of cytotoxicity induced by chimeric mouse human monoclonal antibody IDEC-C2B8 in CD20-expressing lymphoma cell lines显示文摘 | Flieger D Renoth S Beier I | 2000 | Cell Immunol2000，204，1： | 1 |
| 17 | Compliance as a prognostic factor in the treatment of idiopathic scoliosis显示文摘 | Seifert J Selle A Flieger C | 2009 | Orthopade2009，38，2： | 1 |
| 18 | Identification and characterization of a novel monocyte subpopulation in human peripheral blood显示文摘 | Passlick B Flieger D Ziegler-Heitbrock HW | 1989 | Blood1989，74，7： | 1 |
| 19 | Capsule endoscopy in gastro- intestinal lymphomas 显示文摘 | Flieger D Keller R May A | 2005 | Endoscopy2005，37，12： | 1 |
| 20 | Use of Cyclodextrins for the Enantiosective Separation of Ergot Alkaloids by Capillary Zone Electrophoresis 显示文摘 | Fanali S Flieger M Steinerova N | 1992 | Electrophoresis1992，131，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员